

# BTS - International Liver Transplant Oncology Symposium

12th - 13th December 2025

Fetal Medicine Research Institute, King's College Hospital, 16-20 Windsor Walk, Camberwell, SE5 8BB

---

This meeting has been sponsored with funding contributing towards room hire and exhibition stand space only; sponsors have had no input into the educational content of the meeting.

'BTS - International Liver Transplant Oncology Symposium' has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for **14 category 1 (external) CPD credit(s) (code: 153537)** Full conditions of approval are listed in the [guidelines](#).

*This programme is subject to change at the Conference Organisers discretion*



**INTERNATIONAL LIVER  
TRANSPLANTATION SOCIETY**

# Friday 12<sup>th</sup> December

Time	Session	Speaker
09:00	Registration arrival tea/coffee	
09:30	Welcome Address	Krish Menon (UK) Nazia Selzner (USA)
	<b>Liver Transplantation for Colorectal Liver Metastases</b> LT for Unresectable Colorectal Liver Metastases <i>Session Chairs: Nazia Selzner (Canada), Michael Heneghan (UK), Derek Manas (UK)</i>	
09:40	Nordic Experience	Pål-Dag Line (Norway)
09:55	French Experience	René Adam (France)
10:10	North American Experience	Roberto Hernandez Alejandro (USA)
10:25	Canadian Experience	Gonzalo Sapisochin (Spain)
10:40	UK Experience	Krish Menon (UK)
10:55	Panel Discussion: Commonality in listing criteria, tackling recurrent disease	Pål-Dag Line, René Adam, Roberto Hernandez Alejandro, Gonzalo Sapisochin, Krish Menon
11:10	Refreshment Break	
	<b>Liver Transplantation for Colorectal Liver Metastases</b> <i>Session Chairs: Steve White (UK), Paul Ross (UK), Miriam Cortes Cerisuelo (UK)</i>	
11:30	Staged Hepatectomy is superior to Liver Transplantation for advanced Colorectal Liver Metastases	Henrik Perowsky (Zurich)
11:45	LT for Unresectable Colorectal Liver Metastases - The Oncologists View	Jennifer Seligman (UK)
12:05	LT for Unresectable Colorectal Liver Metastases- Picking the Winners!	Karim Halazun (USA)
12:25	Case Presentations	Aarathi Vijayshanker (UK) Satheesh Iype (UK)  Discussants: Dhanny Ghomez (UK) & Zahir Sunavala (UK)
13:00	Lunch Break	
	<b>Liver transplantation for Unresectable Neuroendocrine Liver Metastases</b> <i>Session Chairs: Tahir Shah (UK), Raj Srirajaskanthan (UK), Dinesh Sharma (UK)</i>	
14:00	Liver transplantation for Unresectable Neuroendocrine Liver Metastases – Are the Milan Criteria ready for universal adoption?	Vincenzo Mazzaferro (Italy)

14:15	Resection and not Liver Transplantation is the way forward for Unresectable Neuroendocrine Liver Metastases	Peter Stålberg (Sweden)
14:30	Panel Discussion	Peter Stålberg, Tahir Shah, Raj Srirajaskanthan, Dinesh Sharma, Mohamed Elmasry
14:45	Case Presentation	Mohamed Elmasry (UK)
15:15	Refreshment Break	
	<b>6 Best Free Papers</b> <i>Session Chairs: Alessandro Parente (UK), Rohit Gaurav (UK)</i>	
15:30	RON0 resection for perihilar cholangiocarcinoma offers survival similar to transplantation: A multicentre pan-European study	Aarathi Vijayshanker (UK)
15:50	Evaluating tumour necrosis thresholds for predicting survival and recurrence in liver transplantation for HCC	Mzamo Mbelle (UK)
16:00	A Silent Tumour in a Noisy Liver: Recognizing Hepatocellular Carcinoma Risk in Paediatric PFIC before Liver Transplantation	Amar Qadeer (Pakistan)
16:10	Survival outcome after liver transplantation with Incidental Mixed Hepatocellular-cholangiocarcinoma on explant histopathology: A Systematic Review and Meta-Analysis	Parthiban Durairaj (UK)
16:20	Ruced Transplant Access but Comparable Age-Adjusted Long-Term Outcomes in MASLDAssociated HCC: A UK Registry Analysis	Abdullah Khawaja (UK)
16:30	<b>Global Non-HCC Transplant Oncology Registry</b> <i>Session Chairs: Wojtek Polak (Netherlands), Roberto Hernandez Alejandro (USA)</i>	
	Introduction Outline of the Registry and Proposal Discussion & Next Steps	Krish Menon (UK) Abdul Hakeem (UK) Gonzalo Sapisochin (Spain)
17:15	Closing Remarks	Derek Manas (UK) Valeria Mas (USA)
17:30	Drinks Reception – King's College Hospital Boardroom	Professor Clive Kay (UK)

# Saturday 13<sup>th</sup> December

Time	Session	Speaker
08:45	Registration arrival tea/coffee	
	<b>Intrahepatic and Perihilar Cholangiocarcinoma (CCA)</b> <i>Session Chairs: Steve Fenwick (UK), Rebeca Sanabria Mateos (UK), Douglas Thorburn (UK)</i>	
09:15	LT for Intrahepatic CCA (iCCA)	Majella Doyle (USA)
09:30	LT for Perihilar CCA (PCCA)	Julie Heimbach (USA)
09:45	Liver Transplantation for CCA - the Oncologist's view	Khurum Khan
10:00	UK protocols for Intrahepatic and Perihilar Cholangiocarcinoma	Anya Adair (UK)
10:30	Panel Discussion	Majella Doyle, Julie Heimbach, Khurum Khan, Anya Adair
10:45	Case Presentation	Emir Hoti (ROI)
11:10	Refreshment Break	
	<i>Session Chairs: Parthi Srinivasan (UK), Debashis Sarkar (UK), Joerg-Matthias Pollok (UK)</i>	
11:30	Lessons learnt from pushing the boundaries from LT for HCC	Avi Soin (India)
11:45	RAPID approach to LT for oncology indications	Deniz Balci (Turkey)
12:00	Future Challenges - Immunotherapy and Liver transplantation for Oncological Indications	Parissa Tabrizan (USA)
12:15	Liver Transplantation for Oncological Indications - A 'Molecular Pass' is the Future	Valeria Mas (USA)
12:30	Immunosuppression in LT for oncological indications	Varuna Aluvihare (UK)
12:45	Lunch Break	
	<b>Graft Allocation - Meeting the Challenges</b> <i>Session Chairs: Steve Masson (UK), Charlie Imber (UK), Peter Friend (UK)</i>	
13:30	Liver transplantation for oncological indications - Managing the 'Zero Sum Game'	Nazia Selzner (Canada)
13:45	The North American graft allocation approach for oncological indications	James Pomposelli (USA)
14:00	The UK approach to graft allocation for oncological indications	Ian Rowe (UK)
14:15	Expanding the donor pool with machine perfusion	Wojtek Polak (Netherlands)
14:30	The LDLT approach allows for both expansion of the donor pool and timely liver transplantation for oncological indications	Subhash Gupta (India)
14:45	Balancing survival benefit and justice: ethical issues in liver transplant oncology	Kim Olthoff (USA)
15:00	Panel Discussion	Nadia Selzner, Jim Pomposelli, Ian Rowe, Wojtek Polak, Subhash Gupta, Kim Olthoff
15:30	Refreshment Break	

15:45	<i>Session Chairs: Deniz Balci (Turkey), Alberto Fuyeo Sanchez (UK), Shahid Farid (UK)</i>	
15:45	Debate 1: Should the indications be expanded for LDLT for non-HCC oncological indications	For: Prashant Bhangui (India) Against: Abhi Humar (USA)
16:15	Debate 2: The House believes: 'High rates of recurrence following LT for URCLM does not always negate the benefit of transplant'	For: Pål-Dag Line (Norway) Against: Kymberley Watt (USA)
	<b>Summary</b> <i>Session Chairs: Derek Manas (UK), Nazia Selzner (Canada)</i>	
16:45	LT for Unresectable Colorectal Liver Metastases	Roberto Hernandez Alejandro (USA)
17:00	LT for Unresectable Neuroendocrine Metastases	Raj Srirajaskanthan (UK)
17:15	LT for iCCA and PCCA	Gonzalo Sapiosochin
17:30	Research in LT for Non-HCC oncological indications	Valeria Mas (USA)
17:45	Global Liver Transplant Registry	Krish Menon (UK) & Wojtek Polak (Netherlands)
18:00	Closing Remarks	Krish Menon & Valeria Mas

## Sponsors

This meeting has been sponsored with funding contributing towards room hire and exhibition stand space only; sponsors have had no input into the educational content of the meeting.



**AstraZeneca** is a global, science-led biopharmaceutical company focused on Oncology, Rare Diseases, and Biopharmaceuticals including cardiovascular, Renal & Metabolism, Respiratory & Immunology. With a 100-year UK heritage, today, it's the leading UK biopharmaceutical company, headquartered in Cambridge across five sites. Please visit [www.astrazeneca.co.uk](http://www.astrazeneca.co.uk) and follow us on Twitter @AstraZenecaUK.



Every day, millions of patients and caregivers rely on **Baxter's** leading portfolio of critical care, nutrition, hospital and surgical products. For 90 years, we've been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company's rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations.



**Chiesi Limited** are an international company with a strong focus on innovative medicines in Respiratory, Neonatology, Transplantation and Rare Diseases.

Advances in transplantation have given thousands a second chance at life, but challenges remain, including organ shortages and long-term patient management. Chiesi are committed to supporting healthcare professionals and patients to improve access, outcomes, and ongoing care.

UK-TR-2500095 November 2025



Company profile pending



**Johnson and Johnson Med Tech** develops and delivers innovative medical devices, diagnostics, and digital health solutions that improve patient outcomes worldwide. Combining scientific research, engineering excellence, and clinical partnerships, the company advances surgical systems, cardiovascular care, and minimally invasive therapies while prioritizing safety, quality, and sustainable access to healthcare.



**HistoSonics** is a venture-backed medical device start-up company developing a non-invasive sonic beam therapy platform and procedure using the science of histotripsy. The Edison System delivers tissue-specific treatments with precision and control without the undesirable side effects of many of today's interventional and surgical modalities.



**OrganOx** is a commercial stage organ technology company, spun out of the University of Oxford in 2008, dedicated to developing technologies to improve outcomes for patients with acute or chronic organ failure.



**Q3 Medical Group** is a global medical device company transforming patient journeys through innovative biodegradable and micro-invasive stent technologies. Centered on four pillars — patient quality of life, cost reduction, hospital efficiency, and sustainability — Q3 partners with clinicians worldwide to deliver smarter, more responsible solutions that redefine healthcare pathways.



**Sirtex Medical** is a global healthcare business, working to improve outcomes in people with cancer.

Sirtex' current lead product is SIR-Spheres® Y-90 resin microspheres, a medical device used in Selective Internal Radiation Therapy (SIRT) for treatment of unresectable liver tumors.



For further information please visit [www.sirtex.com](http://www.sirtex.com). SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd

Founded in 1998, XVIVO is the only MedTech company dedicated to extending the life of all major organs – so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of organ transplantation.

XVIVO is a global company headquartered in Gothenburg, Sweden.

DRAFT